Valuation: Lexicon Pharmaceuticals, Inc.

Market Cap 905M 790M 746M 677M 1.27B 86.89B 1.27B 8.93B 3.45B 44.17B 3.4B 3.33B 142B P/E 2026 *
-12.2x
P/E 2027 * -10.9x
Enterprise Value 905M 790M 746M 677M 1.27B 86.89B 1.27B 8.93B 3.45B 44.17B 3.4B 3.33B 142B EV / Sales 2026 *
23.9x
EV / Sales 2027 * 45.5x
Free-Float
98.45%
Yield 2026 *
-
Yield 2027 * -
09-09 Lexicon Pharmaceuticals, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 11:20 AM
08-31 Lexicon Pharmaceuticals Announces Results from Post Hoc Soloist-Whf Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure CI
08-24 Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk DJ
08-24 Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 MT
08-06 Lexicon Pharmaceuticals, Inc., Q2 2026 Earnings Call, Aug 06, 2026
08-06 Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-06 Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss MT
08-06 Earnings Flash (LXRX) Lexicon Pharmaceuticals, Inc. Reports Q2 Revenue $692,000, vs. FactSet Est of $4.0M MT
07-27 Lexicon Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy CI
07-27 Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment MT
06-29 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell Small Cap Comp Growth Benchmark CI
06-29 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2000 Index CI
06-29 Lexicon Pharmaceuticals, Inc.(NasdaqCM:LXRX) added to Russell 2500 Growth Benchmark CI
1 day+0.74%
1 week+1.49%
Current month-8.89%
1 month-12.39%
3 months+0.49%
6 months+26.54%
Current year+78.26%
1 week 1.88
Extreme 1.885
2.11
1 month 1.88
Extreme 1.885
2.48
Current year 1.1
Extreme 1.1
2.68
1 year 1.1
Extreme 1.1
2.68
3 years 0.28
Extreme 0.2836
3.73
5 years 0.28
Extreme 0.2836
6.33
10 years 0.28
Extreme 0.2836
19.62
Manager TitleAgeSince
Chief Executive Officer 56 07/07/2024
Director of Finance/CFO 59 01/01/2025
Chief Tech/Sci/R&D Officer - 31/01/2025
Director TitleAgeSince
Chairman 83 31/12/2004
Chairman 71 26/02/2012
Director/Board Member 67 27/08/2007
Date Insider Type Main position Quantity % Market Cap. Importance
03/06/26 Exercice

Director

178,624 0.0402%
03/06/26 Exercice

Director

178,624 0.0402%
03/06/26 Exercice

Director

178,624 0.0402%
Change 5-day change 1-year change 3-year change Capi.($)
+0.74%+1.49%+88.07%+46.43% 905M
-0.31%+3.56%+46.40%+100.50% 70.89B
+0.39%+1.82%+38.93%+77.73% 62.32B
-3.21%-5.72%-17.12%+350.96% 27.07B
-2.64%-0.35%-2.13%-15.04% 24.78B
+0.71%+8.50%+27.76%-15.29% 20.59B
-1.26%-10.61%+170.72%+290.48% 15.52B
-0.22%+1.62%+44.31%+167.58% 14.49B
+0.73%+5.00%-1.33%+854.55% 14.14B
-0.54%-0.30%+27.33%+202.19% 12.35B
Average -0.56%+1.51%+42.30%+206.01% 26.31B
Weighted average by Cap. -0.58%+1.38%+35.97%+160.94%

Financials

2026 *2027 *
Net sales 37.95M 33.09M 31.24M 28.37M 53.16M 3.64B 53.38M 374M 144M 1.85B 143M 139M 5.96B 19.91M 17.36M 16.4M 14.89M 27.9M 1.91B 28.01M 196M 75.79M 971M 74.8M 73.14M 3.13B
Net income -72.44M -63.17M -59.64M -54.16M -101M -6.95B -102M -714M -276M -3.53B -272M -266M -11.37B -90.96M -79.32M -74.9M -68.01M -127M -8.73B -128M -897M -346M -4.44B -342M -334M -14.28B
Net Debt - -
Logo Lexicon Pharmaceuticals, Inc.
Lexicon Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is engaged in research and development of drug candidates and the commercialization of the drug, INPEFA (sotagliflozin). INPEFA reduces the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease (CKD), and other cardiovascular risk factors. Sotagliflozin is an orally delivered small molecule drug candidate as a treatment for hypertrophic cardiomyopathy (HCM) and conducts the SONATA-HCM pivotal Phase 3 clinical trial of sotagliflozin in that indication. The Company develops pilavapadin, an orally delivered small molecule drug candidate, as a treatment for neuropathic pain. The Company also develops LX9851, an orally delivered small molecule drug candidate, for the treatment of obesity and associated cardiometabolic disorders.
Employees
81
Date Price Change Volume
18/09/26 US$2.050 +0.74% 7,458,732
17/09/26 US$2.035 +0.74% 2,235,727
16/09/26 US$2.020 +0.50% 2,151,590
15/09/26 US$2.010 +1.52% 2,508,532
14/09/26 US$1.980 -1.00% 1,773,837
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
2.035USD
Average target price
3.856USD
Spread / Average Target
+89.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LXRX Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!